Candel Therapeutics Set to Showcase Groundbreaking Findings
NEEDHAM, Mass. — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a forward-thinking clinical-stage biopharmaceutical entity, is generating excitement as it prepares to present pivotal insights derived from its state-of-the-art enLIGHTEN™ Discovery Platform. The presentation will feature additional data from the promising CAN-2409 (aglatimagene besadenovec) initiative focusing on non-small cell lung cancer (NSCLC). These compelling findings are set to be showcased through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting, occurring from November 5-9.
Exciting Presentations Planned
During this significant event, Dr. Paul Peter Tak, M.D., Ph.D., FMedSci, will unveil remarkable results from Candel’s phase 3 clinical trial evaluating CAN-2409 in patients diagnosed with intermediate-to-high-risk localized prostate cancer. This presentation is part of a respected faculty presentation and follows a panel discussion revolving around the modern landscape of cancer immunotherapy, including its future possibilities and challenges.
Detailed Agenda
Poster Presentations
The details of the poster presentations are as follows:
- Title: Integrative discovery of a multimodal cancer immunotherapy using machine learning and viral vector engineering
Presenter: Anne Diers, Ph.D., Vice President, Research, Candel Therapeutics
Abstract Number: 893
Session Date: Friday, Nov. 7
Location: Prince George ABC Exhibit Halls – Gaylord National Resort and Convention - Title: Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC
Presenter: Daniel H. Sterman, M.D., Director, Multidisciplinary Pulmonary Oncology Program, NYU Langone Medical Center
Abstract Number: 513
Session Date: Friday, Nov. 7
Location: Prince George ABC Exhibit Halls – Gaylord National Resort and Convention
Special Faculty Presentation
Title: Phase 3 Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care Radiation Therapy for Newly Diagnosed, Localized Prostate Cancer with Curative Intent
Presenter: Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel Therapeutics
Session: The Next Wave: Viruses, Cells and Next-gen PD-1 Bispecifics
Date/Time: Friday, Nov. 7, 3:55 - 5:35 p.m.
Location: Potomac Ballroom – Gaylord National Resort and Convention
Introducing Candel Therapeutics
Candel Therapeutics is dedicated to evolving the landscape of cancer treatment with its pioneering milestones in developing off-the-shelf multimodal biological immunotherapies. These innovations are designed to generate an individualized, systemic anti-tumor immune response, providing hope to patients battling cancer. With a focus on groundbreaking research, Candel has established impressive clinical-stage biological immunotherapy platforms using novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs.
Among its impressive lineup, CAN-2409 stands out as the primary candidate under the adenovirus platform. Candel has completed successful phase 2a clinical trials for CAN-2409 in both NSCLC and pancreatic ductal adenocarcinoma (PDAC), in addition to a rigorous pivotal phase 3 clinical trial for localized prostate cancer finalized in adherence with a Special Protocol Assessment from the U.S. Food and Drug Administration (FDA). Notably, CAN-2409 has achieved Regenerative Medicine Advanced Therapy Designation from the FDA for newly diagnosed localized prostate cancer and has received enticing Fast Track and Orphan Drug Designations in multiple cancer types, particularly for PDAC.
The Future of Candel’s Research
In addition to CAN-2409, Candel’s pipeline includes CAN-3110 (linoserpaturev), a lead product candidate from the HSV platform currently undergoing phase 1b clinical trials for recurrent high-grade glioma. Early results have drawn interest following their publication, underscoring the ongoing potential of the HSV platform in developing effective cancer treatments. Furthermore, Candel’s enLIGHTEN™ Discovery Platform represents a systematic approach to leveraging human biology and advanced analytics — set to generate innovative viral immunotherapies targeting solid tumors.
Frequently Asked Questions
What is the focus of Candel Therapeutics?
Candel Therapeutics is primarily focused on developing biological immunotherapies that effectively combat cancer through innovative and customized treatment approaches.
Where will Candel be presenting its findings?
Candel will present at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, held in National Harbor.
Who will lead the presentations at the conference?
Dr. Paul Peter Tak, the President and CEO of Candel Therapeutics, will lead the key presentations at the conference.
What can we expect from the data presented?
The presentations will include novel insights from clinical trials and groundbreaking methodologies in cancer treatment applications.
How can I learn more about Candel Therapeutics?
For additional information regarding Candel’s initiatives and research, you can visit their official website at www.candeltx.com.
